Willkie Advises CVC on its Investment in Sebia

October 25, 2017

Paris and London offices advise CVC on its investment in technology provider for in-vitro diagnostic testing.

A cross-border Willkie deal team represented CVC Capital Partners Strategic Opportunities (CVC Stratops) on its acquisition, alongside Téthys Invest, of a controlling stake in Sebia from Astorg and Montagu Private Equity. CVC Stratops and Téthys Invest join the Caisse de Dépôt et Placement du Québec (CDPQ) and Sebia management as shareholders of Sebia. The contemplated transaction remains subject to workers’ council information and consultation and to the approval of relevant regulatory authorities.

Founded in 1967, Sebia is a world-leading provider of clinical protein electrophoresis equipment and reagents, a technology used for in-vitro diagnostic testing. Sebia is headquartered in Lisses, France, and operates across more than 120 countries.

Willkie’s cross-border deal team was led by Paris partner Cédric Hajage, and included Paris: national partner Grégoire Finance, counsel Jeff Fouts, and associates David Lambert and Saint-Loubert-Bié Thomas; and London: UK partner Sebastian FitzGerald.